Fulgent Genetics (FLGT) Receivables - Other (2017 - 2026)

Fulgent Genetics has reported Receivables - Other for 11 years, with the latest figure at $1.5 million in Q2 2026.

• Quarterly Receivables - Other fell 28.85% year-over-year to $1.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.5 million (down 28.85% YoY) and the FY2025 annual result came in at $1.1 million, down 35.86% from the prior year.
• Receivables - Other rose to $1.5 million in Q2 2026 per FLGT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Receivables - Other peaked at $19.8 million in Q4 2022 and troughed at $699000.0 in Q3 2022.
• A 5-year average of $2.4 million and a median of $1.3 million in 2023 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other surged 3467.63% in 2022, then plunged 93.35% in 2023.
• Over 5 years, Receivables - Other stood at $19.8 million in 2022, then slumped by 93.35% to $1.3 million in 2023, then surged by 34.04% to $1.8 million in 2024, then tumbled by 35.86% to $1.1 million in 2025, then climbed by 28.75% to $1.5 million in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $1.5 million, $1.1 million, and $1.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.